Clinical trials
Hepatitis clinical trials
Below are recruiting hepatitis clinical trials, each written for real people, not researchers. We’re tracking 484 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07282093RecruitingPhase 1
Olverembatinib in people with liver problems
This trial tests how a drug called olverembatinib is processed by the body in people with different levels of liver impairment. It looks at how the liver condition affects the drug levels and safety, which may help find the right dose.
Suzhou, JiangsuAges 18–75 - NCT07021534RecruitingPhase 1
CAR-NK and CAR-T cells for cancer with liver spread
This trial tests a new treatment that uses special immune cells (CAR-NK and CAR-T cells) given directly into the liver artery, then through a vein, to fight advanced solid tumors that have spread to the liver. It is for people who have already tried standard treatments and need new options.
Hangzhou, ZhejiangAges 18–75 - NCT07684326RecruitingPhase 2/Phase 3
Can dapagliflozin help liver cirrhosis with fluid buildup? (Phase 2/3 randomized trial)
This trial tests a diabetes pill (dapagliflozin) to see if it helps people with liver cirrhosis and fluid buildup (ascites). The goal is to improve fluid balance and possibly reduce hospital stays.
GizaAges 18 years+ - NCT07746999Enrolling by invitation
Liver health study for transgender adults
This study looks at liver health in transgender individuals to better understand and improve care. You may join if you are 18 or older and can read and write in English.
Newark, New JerseyAges 18 years+ - NCT06923280Recruiting
Sequential Pegylated Interferon After RNA-Targeted Hepatitis B Therapy
This trial tests a sequence of pegylated interferon (PEG-IFN) shots for people with chronic hepatitis B who have already had a significant drop in their virus levels after taking a newer type of RNA-targeting medicine. The goal is to see if this approach can help clear the virus even further.
Beijing, ChinaAges 18–80 - NCT03855917RecruitingPhase 4
Short 4-week hepatitis C treatment for early liver disease
This trial tests whether a very short 4-week course of two hepatitis C drugs (sofosbuvir and glecaprevir-pibrentasvir) can cure hepatitis C in people with early-stage liver disease. The goal is to see if a shorter treatment works as well as longer ones.
Darlinghurst, New South WalesAges 18 years+ - NCT07600788RecruitingPhase 1
Liver Function and Safety Study of AHB-137 Injection
This study tests how a new investigational drug called AHB-137 moves through your body and affects safety in people with mild-to-moderate liver problems compared to people with normal liver function. The goal is to understand if the drug works safely in people whose livers don't work as well as they should.
Chongqing, Chongqing MunicipalityAges 18–65 - NCT04162938Recruiting
Tablet app to help emergency patients learn about hepatitis C
This trial tests whether a patient-friendly electronic app given in the emergency department can increase what you know about hepatitis C and help you move to the next steps of care. It may be most helpful for people who are hepatitis C–positive but don’t yet have clear information about their status.
Baltimore, MarylandAges 18–100 - NCT06825559RecruitingPhase 1
Saroglitazar safety in moderate liver impairment from cholestatic disease
This trial tests how the body processes saroglitazar in people with moderate liver impairment caused by cholestatic liver disease. The goal is to ensure the drug is safe and dosed correctly for this group.
Indianapolis, IndianaAges 18–80 - NCT07728487RecruitingPhase 1
AT-587 safety study in healthy volunteers
This trial tests a new medication called AT-587 in healthy people to see if it is safe and how the body processes it. You may help by participating if you are in good health and meet the basic requirements.
EdegemAges 18–65 - NCT07607769Recruiting
Tremelimumab and Durvalumab for Untreated Advanced Liver Cancer
This Italian study follows patients with advanced liver cancer (hepatocellular carcinoma) who receive a combination immunotherapy treatment called STRIDE for the first time. The trial tracks how well the treatment works, how it affects quality of life, and its safety in people with moderate to severe liver disease.
AnconaAges 18–100 - NCT06755632Recruiting
Hepatic fibrosis or cirrhosis screening trial
This trial screens for liver scarring (fibrosis) or severe scarring (cirrhosis) caused by hepatitis B or C. It aims to find people who may benefit from further care or treatment.
BobignyAges 18 years+ - NCT07717437Recruiting
Liver cancer registry for patients who had vein embolization
This registry collects medical images and health information from patients with liver cancer or liver metastases who had a procedure to block certain liver veins (PVE/HVE). The goal is to learn more about this technique and help future patients.
Chicago, IllinoisAges 18 years+ - NCT05960656RecruitingPhase 1
Study of SGLT2 inhibitor effects on liver sugar production
This trial tests how stopping a type 2 diabetes medication called an SGLT2 inhibitor affects the liver's production of sugar and ketones. It may help understand better ways to manage diabetes.
San Antonio, TexasAges 30–75 - NCT07053293RecruitingEarly Phase 1
Study on diabetes medication and liver sugar production
This study tests how a type of diabetes medicine called SGLT2 inhibitors affects how the liver makes sugar. It may help researchers better understand how to manage blood sugar in people with type 2 diabetes.
San Antonio, TexasAges 30–75 - NCT06796803RecruitingPhase 2/Phase 3
Combination therapy before surgery for liver cancer
This trial tests a combination of immunotherapy (camrelizumab), a targeted drug (rivoceranib), and liver-directed chemotherapy (HAIC) to shrink liver tumors enough to make them removable with surgery. It is for people with intermediate or advanced liver cancer that has not spread outside the liver.
Harbin, HeilongjiangAges 18–75 - NCT05810480Recruiting
Predicting steroid-dependent liver injury with blood test
This study looks at whether a specific blood marker can predict which patients with liver inflammation will need long-term steroid treatment. It may help doctors decide the best treatment for you if you have unexplained liver injury.
AachenAges Any age - NCT03097952Recruiting
Study of people with long-term hepatitis B in real life
This “real-life” study follows people with chronic hepatitis B to better understand their health over time. It may help researchers learn which factors affect outcomes in everyday care.
Changzhou, JiangsuAges Any age - NCT03308916Recruiting
Screening for liver scarring risk using noninvasive tests
This study checks people who are at higher risk for liver scarring by using noninvasive tests. If those tests suggest significant scarring, the study may consider further testing, but not everyone will need a biopsy.
OdenseAges 30–75 - NCT03569826Recruiting
Study for primary biliary cholangitis and autoimmune hepatitis
This study is for people diagnosed with primary biliary cholangitis or autoimmune hepatitis. It aims to learn more about these autoimmune liver conditions and may help guide better care in the future.
Calgary, AlbertaAges 18 years+ - NCT03773887Recruiting
Study of liver inflammation and healing in alcohol-related liver disease
This study compares patterns of liver inflammation and the liver’s healing ability in people with alcohol-related liver disease, using blood tests and (in most cases) a liver tissue sample. It may help doctors better understand what is happening in the liver and how it may recover.
LilleAges 18–70 - NCT03792919RecruitingPhase 4
Stopping long-term hepatitis B medicine vs continuing
This study compares outcomes for people with chronic hepatitis B who have long-term, stable viral suppression: stopping their antiviral medicine versus continuing it. It may help answer whether it’s safe to stop treatment in the right patients.
Hong Kong, Hong Kong SARAges Any age - NCT03811236Recruiting
Test cold exposure to activate body fat and reduce liver fat
This study tests whether controlled cold exposure can activate “brown fat” and affect liver fat buildup. It may help people with excess liver fat, measured on imaging, but it has several health and medication exclusions.
ViennaAges 18–50 - NCT03845205Recruiting
Liver transplant timing study for alcohol-related liver disease
This study compares early versus standard liver transplant timing for people whose liver illness was caused by alcohol use. It looks at treatment outcomes to see which approach helps patients do better.
Baltimore, MarylandAges 18 years+
Hear when a new Hepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatitis?
- Yes. Clin2 currently lists 484 recruiting hepatitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.